Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus
Multiplexed assays for identification of biomarkers and surrogate markers in systemic lupus erythematosus
复制标题
DOI：
10.1191/0961203303lu1017oa
复制
发表时间：
2004-01-01
期刊：
影响因子：
2.6
通讯作者：
Utz, P
中科院分区：
文献类型：
--
作者：
Utz, P
系统性红斑狼疮（SLE）患者的日常临床护理和临床试验研究都迫切需要有效的生物标志物和替代标志物进行监测。SLE很难在临床试验中进行研究，部分原因是这种疾病的异质性太大。很少有有用的标记已经确定，甚至那些历史上一直被认为是有效的最近受到质疑。本报告将重点介绍新兴的多重检测格式的使用，使数百甚至数千分析物同时进行分析。他们的潜力和陷阱监测SLE患者，特别是那些参加临床试验测试新的治疗方法，将进行讨论。
Validated biomarkers and surrogate markers are badly needed for monitoring patients with systemic lupus erythematosus (SLE), both for routine clinical care and for clinical trials research. SLE is difficult to study in clinical trials, in part because the disease is so heterogeneous. Very few useful markers have been identified, and even those that historically have been thought to be valid have been recently questioned. This report will focus on the use of emerging multiplexed assay formats that enable analysis of hundreds or even thousands of analytes simultaneously. Their potential and pitfalls for monitoring patients with SLE, particularly those enrolled in clinical trials testing novel therapeutics, will be discussed.